Progress of hepcidin in low-risk myelodysplastic syndromes
10.3760/cma.j.cn115356-20190801-00149
- VernacularTitle:铁调素在低危骨髓增生异常综合征中的研究进展
- Author:
Qin ZHENG
1
;
Meihong LUO
Author Information
1. 上海中医药大学附属曙光医院宝山分院 上海市宝山区中西医结合医院血液科 201900
- From:
Journal of Leukemia & Lymphoma
2020;29(7):439-441
- CountryChina
- Language:Chinese
-
Abstract:
Ineffective hematopoiesis, inflammation and iron overload are involved in the regulation of iron metabolism in myelodysplastic syndromes (MDS). Different types of MDS present different iron states at different stages, hepcidin play a key role in it. Current studies have demonstrated that iron metabolism abnormality is an independent risk factor for the prognosis of low-risk MDS. This article summarizes the research progress of hepcidin in patients with low-risk MDS and further explores the therapeutic prospects of hepcidin in patients with low-risk MDS.
